A New Light on Hair Loss
You notice more hair in your brush than usual. It clings to your pillow and clogs the shower drain. This isn’t just a bad hair day—it’s a constant worry. This condition is called telogen effluvium (TE), a type of hair loss where more hairs than normal fall out. It’s often triggered by stress, illness, or childbirth. While it usually resolves on its own, the waiting can be frustrating.
Now, a small study suggests a gentle laser treatment might help speed up recovery. It’s a non-invasive option that could offer hope to those who feel stuck in a cycle of shedding.
Telogen effluvium affects millions of people. It can cause significant emotional distress. Unlike pattern baldness, TE causes diffuse thinning all over the scalp. The hair follicles are pushed into a resting phase too early, leading to widespread shedding.
Current treatments often focus on managing stress and nutrition. But for many, these steps aren’t enough to stop the shedding quickly. Patients often ask for something to help their hair grow back faster. This study explores a potential tool to do just that.
The Old Way vs. The New Way
Traditionally, doctors have advised patients with TE to wait it out. The condition is often self-limiting, meaning it resolves without treatment. There are no specific FDA-approved drugs for TE. Some use minoxidil, but it’s not designed for this type of hair loss and can have side effects.
But here’s the twist: researchers are now looking at light therapy. Photobiomodulation uses specific wavelengths of light to stimulate cells. It’s been used for other hair disorders, but its role in TE was unclear. This study tests a specific laser wavelength—675 nanometers—as a targeted approach.
Think of your hair follicles like tiny factories. In TE, these factories are on an unscheduled break. The laser light acts like a gentle signal, telling the factories to reopen and get back to work.
The 675-nm wavelength is absorbed by the cells’ mitochondria—the power plants of the cell. This boosts energy production, helping the follicles transition from the resting phase back to the growth phase. It’s like giving a sleepy factory a fresh cup of coffee and a pep talk. The process is non-invasive and painless.
Researchers in Mexico reviewed the records of 13 patients diagnosed with TE at a dermatology laser center. All patients received treatment with a 675-nm diode laser in addition to their usual care. The study looked at how their symptoms changed over time.
The patients had chronic TE, meaning their shedding lasted for more than six months. The laser was applied to the scalp during several sessions. The researchers tracked changes in hair shedding, scalp comfort, and a simple pull test.
The results were encouraging. Among patients who had a positive pull test at the start—meaning gentle tugging pulled out several hairs—72% had a negative test at follow-up. This suggests the shedding had slowed down significantly.
Symptoms also improved. Pruritus (itchy scalp) got better in 83% of patients who had it. Trichodynia, or pain and tenderness of the scalp, resolved in 75% of cases. Most importantly, no adverse events were reported. The treatment was well-tolerated.
But there’s a catch.
This was a small study of only 13 patients. It didn’t include a control group, so we can’t be sure the laser alone caused the improvements. Other factors, like time or other treatments, could have played a role.
The researchers concluded that 675-nm diode laser therapy appears safe and potentially effective as an add-on treatment for TE. However, they stress that this is early evidence. Larger, controlled studies are needed to confirm these findings and determine the best treatment protocol.
This treatment is not yet a standard option for TE. It’s still in the research phase. If you are experiencing hair shedding, the best step is to talk to a dermatologist. They can help identify the cause and discuss all available options, including any emerging therapies.
The study’s main limitation is its small size and retrospective nature. It looked back at past patient data rather than testing a new treatment in a controlled setting. The findings are promising but not definitive. More research is needed to understand how well this works for different types of TE.
Next steps would involve larger clinical trials with more patients and a control group. Researchers will need to standardize the laser treatment protocol—how many sessions, how long, and at what intensity. If these trials are successful, this laser therapy could become a helpful tool in the dermatologist’s toolkit for managing TE.
